VVOS

$1.32

Market ClosedAs of Mar 17, 8:00 PM UTC

Vivos Therapeutics, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.32
Potential Upside
5%
Whystock Fair Value$1.39
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a n...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$15.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
7.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-335.45%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.70

Recent News

Zacks
Mar 12, 2026

Health Catalyst (HCAT) Lags Q4 Earnings Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of -14.26% and +1.45%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 3, 2026

Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Jan 5, 2026

Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know

Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 27, 2025

Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ...

Vivos Therapeutics Inc (VVOS) reports a 76% revenue increase in Q3 2025, driven by strategic acquisitions and expanded service offerings.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 10, 2025

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.56% and +14.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.